Women who inherit a deleterious BRCA1 or BRCA2 mutation face substantially increased
risks of developing breast cancer, which is estimated at 70%. Although annual screening …

It has been 10 years since the BRCA1 gene was first identified. During this decade, genetic
testing for breast cancer susceptibility has been incorporated into the practice of oncology. In …

The purpose of our study was to review the evidence for the efficacy of surveillance for early
detection, bilateral prophylactic mastectomy, prophylactic oophorectomy and …

Genetic testing for BRCA1 and BRCA2 mutations is gaining acceptance in clinical oncology
worldwide and may help target unaffected high-risk women for prevention and for close …

Genetic testing for BRCA mutations is expanding in clinical oncology centers worldwide.
Testing may help target unaffected high-risk women for prevention and/or close surveillance …

The presence of breast cancer in any first-degree female relative in general nearly doubles
the risk for a proband and the risk gradually increases with the number of affected relatives …

Objective Conflicting conclusions have been published regarding breast cancer survival of
BRCA1/2 mutation carriers. Here we provide an evidence-based systematic literature …

BRCA mutation–associated breast cancer differs from sporadic breast cancer with regard to
future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for …

This study prospectively evaluated the utilization of cancer risk management strategies in a
multi‐institutional cohort of BRCA1 and BRCA2 mutation carriers using a self‐report …

Background: The contribution of BRCA germline mutational status to breast cancer patients'
prognosis is unclear. We aimed to systematically review and perform meta-analysis of the …